Mannkind

sloppy, i totally agree w/ you re: launch. anyone who hasn't played a bio stock that tried to launch w/o existing sales force would not understand how agonizing this can be. I recall when KOSP (subsequently bot out) launched niaspan. we learned how to track the weekly and monthly prescriptions through 3rd party tracking services. then there is the everpresent prospect of "renting" a sales force from someone like takeda. all the while you are bleeding cash while the greatest product on earth is running out of patent protection.

rak